{
    "ticker": "QTRX",
    "name": "Quanterix Corporation",
    "description": "Quanterix Corporation is a leading innovator in life sciences technology, dedicated to advancing the field of precision medicine through its proprietary digital immunoassay platform. Founded in 2007, Quanterix aims to transform the way diseases are diagnosed and treated by providing highly sensitive and specific measurements of biomarkers at ultra-low concentrations. The company's flagship product, the Simoa (Single Molecule Array) technology, enables the detection of proteins at levels that were previously unattainable, which is crucial for early disease detection, monitoring treatment response, and understanding disease progression. Quanterix's solutions are used in various applications, including oncology, neurology, and cardiology, making it a pivotal player in the shift towards personalized medicine. With a commitment to scientific innovation and collaboration, Quanterix partners with pharmaceutical companies, academic institutions, and research organizations to accelerate drug development and improve patient outcomes. The company is also engaged in efforts to expand its product offerings and increase accessibility to its assays, thereby contributing to a future where precision medicine is the standard of care.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Billerica, Massachusetts, USA",
    "founded": "2007",
    "website": "https://www.quanterix.com",
    "ceo": "Evan Jones",
    "social_media": {
        "twitter": "https://twitter.com/Quanterix",
        "linkedin": "https://www.linkedin.com/company/quanterix/"
    },
    "investor_relations": "https://investors.quanterix.com",
    "key_executives": [
        {
            "name": "Evan Jones",
            "position": "CEO"
        },
        {
            "name": "David D. H. Tatum",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunoassay Technology",
            "products": [
                "Simoa HD-1 Analyzer",
                "Simoa Biomarker Panels"
            ]
        },
        {
            "category": "Research Services",
            "products": [
                "Custom Assays",
                "Clinical Research Support"
            ]
        }
    ],
    "seo": {
        "meta_title": "Quanterix Corporation | Precision Medicine and Biomarker Detection",
        "meta_description": "Explore Quanterix Corporation, a leader in precision medicine and digital immunoassays. Learn about our innovative technologies and their impact on healthcare.",
        "keywords": [
            "Quanterix",
            "Precision Medicine",
            "Biomarkers",
            "Immunoassays",
            "Simoa Technology"
        ]
    },
    "faq": [
        {
            "question": "What does Quanterix specialize in?",
            "answer": "Quanterix specializes in precision medicine through its advanced digital immunoassay technology."
        },
        {
            "question": "Who is the CEO of Quanterix?",
            "answer": "Evan Jones is the CEO of Quanterix Corporation."
        },
        {
            "question": "Where is Quanterix headquartered?",
            "answer": "Quanterix is headquartered in Billerica, Massachusetts, USA."
        },
        {
            "question": "What are the main products of Quanterix?",
            "answer": "Quanterix's main products include the Simoa HD-1 Analyzer and various biomarker panels."
        },
        {
            "question": "When was Quanterix founded?",
            "answer": "Quanterix was founded in 2007."
        }
    ],
    "competitors": [
        "RGEN",
        "NVTA",
        "NTRA",
        "ILMN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "MRNA"
    ]
}